Business Wire

Executives Remain Committed to Integrating Financial and Sustainability Data, Citing Strong Benefits Despite Policy Uncertainty, New Workiva Study Finds

Share

Companies that integrate financial and sustainability data are gaining a competitive edge. According to Workiva Inc.’s (NYSE: WK) 2025 Executive Benchmark Survey of 1,600 global leaders, 97% of executives say sustainability reporting will be a business advantage within two years, and 96% of investors agree it strengthens financial performance.

Despite policy uncertainty, leaders are not changing course. Over 10,000 companies and institutions (a 29% year-over-year increase) have set science-based decarbonization targets or committed to doing so, while 24 U.S. States and over 190 countries remain aligned with the Paris Climate Agreement, signaling that long-term commitments are holding firm.

Executives see integrated reporting as essential for resilience and growth. “CEOs are making choices today that will shape their business for years to come,” said Julie Iskow, CEO of Workiva. “Assured financial and sustainability reporting is not simply a compliance play, it's a strategic approach to mitigate risk, fuel performance, and strengthen investor confidence.”

Investors are responding. “The market has spoken and forward-thinking companies aren’t waiting - they’re taking action and committing to science-based targets and stronger disclosures,” said Tensie Whelan, Distinguished Professor of Practice for Business and Society and Founding Director of the NYU Stern Center for Sustainable Business. “They understand that sustainability and integrated reporting isn’t just about risk management, it’s a competitive advantage that attracts capital and drives long-term success.”

Key Findings:

  • 97% of executives say integrated financial and sustainability data helps identify performance gaps that enhance financial growth opportunities.
  • 85% will move forward with climate disclosures, regardless of political shifts.
  • 92% of investors rank data accuracy as a foundational requirement to effectively evaluate organizations, yet nearly a quarter of executives do not fully trust their financial data.
  • 93% of institutional investors are more likely to invest in companies with integrated financial and non-financial reporting.

Executive Perspectives:

The business case for integrated data and reporting is stronger than ever. "By making our operations more sustainable, we're able to increase efficiencies that impact our bottom line. It’s a direct cause-and-effect relationship,” said Allyson Anderson Book, CSO at Baker Hughes. “As we continue to enhance our sustainability efforts and move forward with climate disclosures and sustainability reporting, we believe our investor-grade integrated ESG data and reporting demonstrates our long-term, transparent approach to our investors.”

European leaders see regulatory shifts as an opportunity: "The CSRD is a game changer that empowers us to manage and report on our sustainability ambitions and results on a new level. The double materiality assessment where financial and impact materiality is combined has been a great support for us in the quest of identifying key risks and opportunities that drive long-term value creation. When CFO and CSO teams align around these material topics and metrics, we make better decisions and drive stronger performance," said Ida Bohman Steenberg, Chief Sustainability Officer of Tietoevry.

CEMEX Chief Financial Officer Maher Al-Haffar echoed the sentiment: “Other Chief Financial Officers and Chief Executive Officers that I talk to believe that sustainability is something that we cannot ignore. Sustainability is incredibly important because it contributes to the profitability of the business. As a CFO, I’m trying to get my hands around how to provide data for investors so that they can quantify it and model it.”

The survey results and recent actions by global leaders demonstrate that despite market complexities, executive commitment to assured integrated reporting continues to accelerate, driven by clear evidence of its strategic and financial value.

More Information

Read Workiva’s 2025 Executive Benchmark Survey here. For additional insights, join Workiva and Deloitte for a webinar on March 26, 2025. Click here to register.

About Workiva

Workiva Inc. (NYSE: WK) is on a mission to power transparent reporting for a better world. We build and deliver the world’s leading cloud platform for assured integrated reporting to meet stakeholder demands for action, transparency, and disclosure of financial and non-financial data. Workiva offers the only unified SaaS platform that brings customers’ financial, sustainability, and Governance, Risk, and Compliance (GRC) data and reporting together in a controlled, secure, audit-ready platform. Our platform simplifies the most complex reporting and disclosure challenges by streamlining processes, connecting data and teams, and ensuring consistency. Learn more at workiva.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212682971/en/

Contacts

Media Contact
press@workiva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye